Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints.

Tibolone has been shown to alleviate climacteric symptoms. This study was designed to compare the effect of tibolone (Livial, 2.5 mg daily) on different climacteric complaints and its impact on the endometrium, determined by vaginal ultrasound, with that of conjugated estrogens (Premarin, 0.625 mg daily) continuously for 6 months in combination with the progestogen medrogestone (Colpron, 2 x 5 mg daily for 12 days each month).
One hundred and twenty-nine postmenopausal women were recruited and the severity of climacteric symptoms as well as endometrial thickness were recorded at the pre-trial examination and after 1, 3, and 6 months.
With the exception of vertigo, mood depression, mood disorder, loss of libido, and dryness of skin, where tibolone was found to be more effective than conjugated estrogens/medrogestone, climacteric symptoms improved significantly in both groups over the 6-month study period. Endometrial thickness did not increase significantly in the tibolone group, whereas in the conjugated estrogens/medrogestone group there was a highly significant increase after 1 month and still a trend towards significance after 6 months. Recurrence of vaginal bleeding occurred significantly less frequently in the tibolone group than in the comparison group.
Tibolone seems to offer a complete treatment of the climacteric complaints whilst avoiding some of the problems associated with classical hormone replacement therapy.
AuthorsC Egarter, J Huber, R Leikermoser, R Haidbauer, H Pusch, F Fischl, M Putz
JournalMaturitas (Maturitas) Vol. 23 Issue 1 Pg. 55-62 (Feb 1996) ISSN: 0378-5122 [Print] IRELAND
PMID8861087 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Estrogens
  • Norpregnenes
  • Progestins
  • tibolone
  • Climacteric (drug effects, physiology)
  • Dose-Response Relationship, Drug
  • Endometrium (anatomy & histology, drug effects, ultrasonography)
  • Estrogens (adverse effects, standards, therapeutic use)
  • Female
  • Humans
  • Incidence
  • Middle Aged
  • Norpregnenes (adverse effects, standards, therapeutic use)
  • Progestins (adverse effects, standards, therapeutic use)
  • Surveys and Questionnaires
  • Time Factors
  • Uterine Hemorrhage (drug therapy, epidemiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: